Nurix Therapeutics, Inc

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix

Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies

Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies

Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:

Nurix Therapeutics to Present at Upcoming Investor Conferences

SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition

SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company's Board of Directors effective November 1, 2020. Dr. Tjian (“Tij”) has served as a member of our Board of Directors since November 2016. Dr. Tjian will continue to provide guidance and advice to Nurix in his new role as Chairman of Nurix's Scientific Advisory Board.

Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors

Completed recent IPO raising approximately $238 .5 million in gross proceeds

Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update

SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.

Nurix Therapeutics shares slide 2.3% in trading debut

News for Nurix Therapeutics, Inc Stock (NRIX)